 Paul Norman
Concepts (726)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, KIR | 59 | 2025 | 98 | 10.520 |
Why?
| | Killer Cells, Natural | 55 | 2025 | 444 | 7.230 |
Why?
| | Haplotypes | 44 | 2025 | 487 | 4.440 |
Why?
| | Alleles | 48 | 2025 | 888 | 3.860 |
Why?
| | Genes, MHC Class I | 12 | 2022 | 35 | 3.610 |
Why?
| | Histocompatibility Antigens Class I | 17 | 2024 | 203 | 3.520 |
Why?
| | HLA Antigens | 21 | 2024 | 237 | 3.200 |
Why?
| | HLA-B Antigens | 21 | 2025 | 62 | 3.100 |
Why?
| | HLA-C Antigens | 19 | 2024 | 35 | 3.080 |
Why?
| | Polymorphism, Genetic | 32 | 2024 | 652 | 2.600 |
Why?
| | Receptors, KIR3DL1 | 13 | 2024 | 18 | 2.310 |
Why?
| | Genotype | 36 | 2025 | 1906 | 2.170 |
Why?
| | Immunogenetics | 5 | 2024 | 7 | 2.130 |
Why?
| | Receptors, KIR2DL1 | 12 | 2024 | 19 | 2.110 |
Why?
| | Evolution, Molecular | 18 | 2022 | 488 | 1.790 |
Why?
| | Genetic Variation | 19 | 2025 | 986 | 1.390 |
Why?
| | High-Throughput Nucleotide Sequencing | 15 | 2025 | 536 | 1.370 |
Why?
| | Selection, Genetic | 12 | 2024 | 262 | 1.360 |
Why?
| | HLA-A Antigens | 11 | 2023 | 56 | 1.320 |
Why?
| | Receptors, KIR3DS1 | 4 | 2022 | 6 | 1.270 |
Why?
| | Employment | 4 | 2025 | 177 | 1.250 |
Why?
| | Humans | 199 | 2025 | 136898 | 1.220 |
Why?
| | Receptors, Immunologic | 10 | 2021 | 223 | 1.150 |
Why?
| | Socioeconomic Factors | 8 | 2024 | 1279 | 1.140 |
Why?
| | Amyotrophic Lateral Sclerosis | 6 | 2025 | 87 | 1.110 |
Why?
| | Health Status Disparities | 6 | 2024 | 284 | 1.100 |
Why?
| | Chromosomes, Human, Pair 6 | 2 | 2025 | 54 | 1.050 |
Why?
| | Retirement | 2 | 2025 | 31 | 1.020 |
Why?
| | Genes, MHC Class II | 2 | 2017 | 74 | 1.010 |
Why?
| | Gene Frequency | 19 | 2025 | 521 | 0.990 |
Why?
| | Qualitative Research | 8 | 2025 | 1335 | 0.980 |
Why?
| | England | 12 | 2025 | 99 | 0.940 |
Why?
| | United Kingdom | 13 | 2025 | 322 | 0.920 |
Why?
| | Sequence Deletion | 1 | 2025 | 183 | 0.900 |
Why?
| | Immunogenetic Phenomena | 2 | 2022 | 7 | 0.870 |
Why?
| | Medication Errors | 1 | 2024 | 96 | 0.870 |
Why?
| | Genome, Human | 6 | 2025 | 422 | 0.860 |
Why?
| | Residence Characteristics | 3 | 2021 | 350 | 0.850 |
Why?
| | Focus Groups | 3 | 2024 | 500 | 0.820 |
Why?
| | Pre-Eclampsia | 3 | 2020 | 191 | 0.810 |
Why?
| | Multimorbidity | 1 | 2023 | 47 | 0.810 |
Why?
| | Ligands | 15 | 2023 | 665 | 0.800 |
Why?
| | Herpesviridae | 1 | 2022 | 23 | 0.770 |
Why?
| | Receptors, Natural Killer Cell | 6 | 2022 | 16 | 0.770 |
Why?
| | Genome-Wide Association Study | 4 | 2024 | 1434 | 0.750 |
Why?
| | Adaptation, Psychological | 7 | 2024 | 644 | 0.750 |
Why?
| | Quality of Life | 15 | 2025 | 2847 | 0.750 |
Why?
| | Binge Drinking | 2 | 2021 | 42 | 0.750 |
Why?
| | Minority Groups | 5 | 2024 | 269 | 0.740 |
Why?
| | Primates | 3 | 2019 | 125 | 0.740 |
Why?
| | Health Promotion | 6 | 2024 | 744 | 0.730 |
Why?
| | Herpesviridae Infections | 1 | 2023 | 148 | 0.730 |
Why?
| | Patient Safety | 1 | 2024 | 305 | 0.720 |
Why?
| | Communicable Diseases | 1 | 2023 | 160 | 0.700 |
Why?
| | Seizures | 4 | 2019 | 427 | 0.700 |
Why?
| | Hearing Aids | 1 | 2021 | 79 | 0.680 |
Why?
| | CD8-Positive T-Lymphocytes | 4 | 2023 | 916 | 0.670 |
Why?
| | Mortality | 2 | 2014 | 357 | 0.670 |
Why?
| | Major Histocompatibility Complex | 4 | 2025 | 231 | 0.670 |
Why?
| | Censuses | 3 | 2017 | 31 | 0.660 |
Why?
| | Cross-Sectional Studies | 15 | 2024 | 5398 | 0.650 |
Why?
| | Aortic Aneurysm, Abdominal | 3 | 2017 | 140 | 0.650 |
Why?
| | Genetics, Population | 10 | 2021 | 206 | 0.650 |
Why?
| | Somatoform Disorders | 2 | 2016 | 42 | 0.630 |
Why?
| | Intensive Care Units | 1 | 2024 | 795 | 0.620 |
Why?
| | Hematopoietic Stem Cell Transplantation | 6 | 2024 | 613 | 0.610 |
Why?
| | Peptides | 4 | 2022 | 981 | 0.600 |
Why?
| | Histocompatibility Antigens Class II | 2 | 2023 | 368 | 0.600 |
Why?
| | Male | 67 | 2025 | 67308 | 0.600 |
Why?
| | Poverty Areas | 2 | 2019 | 39 | 0.590 |
Why?
| | Point Mutation | 3 | 2017 | 234 | 0.590 |
Why?
| | Hearing Loss | 1 | 2021 | 221 | 0.580 |
Why?
| | Receptors, KIR2DL4 | 3 | 2016 | 4 | 0.580 |
Why?
| | Female | 74 | 2025 | 72703 | 0.580 |
Why?
| | Adult | 50 | 2025 | 37595 | 0.570 |
Why?
| | Heterozygote | 1 | 2019 | 291 | 0.570 |
Why?
| | Pan troglodytes | 9 | 2017 | 61 | 0.570 |
Why?
| | Blood Vessel Prosthesis Implantation | 2 | 2022 | 202 | 0.560 |
Why?
| | Language | 1 | 2020 | 299 | 0.560 |
Why?
| | Psoriasis | 3 | 2024 | 102 | 0.560 |
Why?
| | Genetic Predisposition to Disease | 13 | 2025 | 2416 | 0.550 |
Why?
| | Health Status | 3 | 2025 | 782 | 0.550 |
Why?
| | Complement C4 | 1 | 2017 | 27 | 0.540 |
Why?
| | Genotyping Techniques | 4 | 2025 | 75 | 0.540 |
Why?
| | Leukemia | 1 | 2019 | 238 | 0.530 |
Why?
| | Rural Health Services | 3 | 2025 | 127 | 0.530 |
Why?
| | Protein Binding | 10 | 2019 | 2222 | 0.520 |
Why?
| | Mucins | 1 | 2017 | 74 | 0.520 |
Why?
| | Linkage Disequilibrium | 10 | 2017 | 268 | 0.510 |
Why?
| | Endovascular Procedures | 2 | 2022 | 310 | 0.500 |
Why?
| | Burns | 3 | 2024 | 317 | 0.490 |
Why?
| | Blood Vessel Prosthesis | 2 | 2022 | 127 | 0.490 |
Why?
| | Middle Aged | 43 | 2025 | 33118 | 0.490 |
Why?
| | Weight Loss | 3 | 2019 | 765 | 0.490 |
Why?
| | Population Dynamics | 2 | 2018 | 149 | 0.490 |
Why?
| | Immunoglobulin Fc Fragments | 2 | 2015 | 40 | 0.490 |
Why?
| | Immunoglobulins | 4 | 2023 | 171 | 0.480 |
Why?
| | DNA Copy Number Variations | 5 | 2025 | 182 | 0.470 |
Why?
| | Family Relations | 1 | 2015 | 89 | 0.470 |
Why?
| | Exons | 1 | 2016 | 349 | 0.460 |
Why?
| | Polymorphism, Single Nucleotide | 12 | 2025 | 2175 | 0.460 |
Why?
| | Population | 1 | 2014 | 35 | 0.450 |
Why?
| | Self Concept | 3 | 2024 | 260 | 0.430 |
Why?
| | Wales | 5 | 2025 | 25 | 0.430 |
Why?
| | Receptors, KIR2DL2 | 5 | 2021 | 6 | 0.430 |
Why?
| | Blood Flow Velocity | 1 | 2015 | 412 | 0.430 |
Why?
| | Receptors, KIR2DL3 | 6 | 2017 | 9 | 0.420 |
Why?
| | Terminally Ill | 1 | 2014 | 37 | 0.420 |
Why?
| | Immunity, Innate | 7 | 2024 | 832 | 0.420 |
Why?
| | Behavior Therapy | 4 | 2023 | 262 | 0.420 |
Why?
| | Sequence Analysis, DNA | 8 | 2025 | 811 | 0.420 |
Why?
| | Emergency Service, Hospital | 7 | 2025 | 2033 | 0.410 |
Why?
| | Malaria | 1 | 2013 | 64 | 0.410 |
Why?
| | Cell Line | 8 | 2019 | 2847 | 0.400 |
Why?
| | Overweight | 1 | 2017 | 554 | 0.400 |
Why?
| | Longitudinal Studies | 9 | 2025 | 2844 | 0.400 |
Why?
| | Histocompatibility Testing | 4 | 2024 | 126 | 0.400 |
Why?
| | Stents | 2 | 2022 | 524 | 0.390 |
Why?
| | Young Adult | 20 | 2024 | 13157 | 0.390 |
Why?
| | Empathy | 2 | 2024 | 180 | 0.380 |
Why?
| | Recombinant Proteins | 1 | 2015 | 1357 | 0.370 |
Why?
| | Aged | 26 | 2025 | 23641 | 0.370 |
Why?
| | Depression | 3 | 2023 | 1402 | 0.370 |
Why?
| | Intention | 3 | 2021 | 171 | 0.360 |
Why?
| | Infant Mortality | 2 | 2024 | 115 | 0.360 |
Why?
| | Cytomegalovirus | 3 | 2024 | 160 | 0.360 |
Why?
| | Molecular Sequence Data | 14 | 2014 | 2901 | 0.350 |
Why?
| | Life Style | 4 | 2017 | 480 | 0.350 |
Why?
| | Emergency Medicine | 2 | 2024 | 224 | 0.350 |
Why?
| | T-Lymphocytes | 6 | 2024 | 1996 | 0.350 |
Why?
| | Universities | 3 | 2021 | 431 | 0.340 |
Why?
| | Behcet Syndrome | 2 | 2021 | 18 | 0.340 |
Why?
| | Alcoholism | 1 | 2017 | 798 | 0.340 |
Why?
| | Health Behavior | 6 | 2025 | 761 | 0.330 |
Why?
| | Biological Evolution | 5 | 2019 | 466 | 0.330 |
Why?
| | Epitopes | 8 | 2019 | 479 | 0.330 |
Why?
| | Patient Compliance | 3 | 2025 | 586 | 0.330 |
Why?
| | Motor Neuron Disease | 2 | 2019 | 20 | 0.320 |
Why?
| | Amino Acid Sequence | 9 | 2019 | 2143 | 0.320 |
Why?
| | Australia | 4 | 2024 | 313 | 0.310 |
Why?
| | Body Image | 3 | 2024 | 95 | 0.310 |
Why?
| | Malnutrition | 2 | 2021 | 82 | 0.310 |
Why?
| | Recombination, Genetic | 2 | 2010 | 198 | 0.310 |
Why?
| | Cytomegalovirus Infections | 2 | 2024 | 194 | 0.310 |
Why?
| | Meiosis | 1 | 2009 | 80 | 0.300 |
Why?
| | Models, Molecular | 5 | 2019 | 1586 | 0.300 |
Why?
| | Antigens, CD | 5 | 2017 | 524 | 0.300 |
Why?
| | Rural Population | 2 | 2018 | 561 | 0.300 |
Why?
| | Urban Population | 1 | 2011 | 470 | 0.300 |
Why?
| | Adolescent | 19 | 2024 | 21402 | 0.290 |
Why?
| | Phylogeny | 12 | 2017 | 897 | 0.290 |
Why?
| | Alcohol Drinking | 4 | 2021 | 823 | 0.290 |
Why?
| | Life Change Events | 2 | 2019 | 153 | 0.290 |
Why?
| | Energy Intake | 3 | 2025 | 473 | 0.280 |
Why?
| | Students | 3 | 2021 | 625 | 0.280 |
Why?
| | Chronic Disease | 1 | 2014 | 1773 | 0.280 |
Why?
| | Genomics | 6 | 2025 | 790 | 0.280 |
Why?
| | Object Attachment | 2 | 2019 | 43 | 0.280 |
Why?
| | China | 3 | 2024 | 218 | 0.280 |
Why?
| | Oceania | 2 | 2024 | 4 | 0.270 |
Why?
| | Income | 2 | 2019 | 201 | 0.270 |
Why?
| | Homozygote | 2 | 2025 | 203 | 0.270 |
Why?
| | Signal Transduction | 4 | 2019 | 5077 | 0.270 |
Why?
| | Self-Management | 2 | 2019 | 171 | 0.260 |
Why?
| | Multigene Family | 3 | 2018 | 202 | 0.260 |
Why?
| | Immune System | 2 | 2019 | 177 | 0.260 |
Why?
| | Egypt | 2 | 2023 | 11 | 0.260 |
Why?
| | Infant, Newborn | 7 | 2024 | 6043 | 0.260 |
Why?
| | Caregivers | 4 | 2025 | 865 | 0.260 |
Why?
| | Centromere | 3 | 2025 | 58 | 0.250 |
Why?
| | Infant | 8 | 2024 | 9408 | 0.250 |
Why?
| | HLA-A24 Antigen | 2 | 2024 | 6 | 0.250 |
Why?
| | Quality Improvement | 2 | 2024 | 1154 | 0.250 |
Why?
| | Virus Activation | 2 | 2024 | 89 | 0.250 |
Why?
| | Phenotype | 8 | 2024 | 3201 | 0.250 |
Why?
| | Codon | 2 | 2016 | 90 | 0.250 |
Why?
| | Amino Acid Substitution | 5 | 2016 | 309 | 0.250 |
Why?
| | Fatigue Syndrome, Chronic | 1 | 2025 | 17 | 0.240 |
Why?
| | Software | 4 | 2025 | 670 | 0.240 |
Why?
| | Thymus Gland | 2 | 2024 | 312 | 0.240 |
Why?
| | Child | 11 | 2024 | 21896 | 0.240 |
Why?
| | Animals | 28 | 2024 | 36914 | 0.240 |
Why?
| | Rural Health | 1 | 2025 | 79 | 0.230 |
Why?
| | Hominidae | 2 | 2019 | 85 | 0.230 |
Why?
| | Industry | 1 | 2025 | 68 | 0.230 |
Why?
| | Occupations | 1 | 2024 | 48 | 0.230 |
Why?
| | Capacity Building | 1 | 2025 | 62 | 0.230 |
Why?
| | Smoking | 5 | 2019 | 1633 | 0.220 |
Why?
| | Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 1 | 2024 | 17 | 0.220 |
Why?
| | Interpersonal Relations | 2 | 2019 | 410 | 0.220 |
Why?
| | Myocardial Infarction | 2 | 2023 | 1044 | 0.220 |
Why?
| | Obesity | 1 | 2017 | 2966 | 0.220 |
Why?
| | Attitude to Health | 3 | 2019 | 444 | 0.220 |
Why?
| | Iodine Radioisotopes | 1 | 2024 | 145 | 0.220 |
Why?
| | Nutrition Therapy | 2 | 2025 | 37 | 0.220 |
Why?
| | Phenylurea Compounds | 1 | 2024 | 95 | 0.220 |
Why?
| | Parkinson Disease | 2 | 2020 | 495 | 0.210 |
Why?
| | Pedigree | 1 | 2025 | 509 | 0.210 |
Why?
| | Arabs | 2 | 2020 | 8 | 0.210 |
Why?
| | Cohort Studies | 8 | 2021 | 5711 | 0.210 |
Why?
| | Quinolines | 2 | 2024 | 176 | 0.210 |
Why?
| | Registries | 4 | 2021 | 2006 | 0.210 |
Why?
| | Alopecia Areata | 1 | 2023 | 13 | 0.210 |
Why?
| | HLA-DP beta-Chains | 1 | 2023 | 85 | 0.210 |
Why?
| | Immunity, Cellular | 1 | 2005 | 267 | 0.210 |
Why?
| | Waiting Lists | 1 | 2025 | 261 | 0.200 |
Why?
| | Efficiency, Organizational | 2 | 2025 | 136 | 0.200 |
Why?
| | Gene Dosage | 3 | 2021 | 148 | 0.200 |
Why?
| | Iran | 2 | 2020 | 41 | 0.200 |
Why?
| | Incidence | 5 | 2020 | 2783 | 0.200 |
Why?
| | Social Stigma | 1 | 2024 | 132 | 0.200 |
Why?
| | Computational Biology | 2 | 2025 | 644 | 0.200 |
Why?
| | Unemployment | 1 | 2022 | 44 | 0.200 |
Why?
| | Transplantation Conditioning | 1 | 2024 | 170 | 0.200 |
Why?
| | Cardiovascular Diseases | 3 | 2021 | 2110 | 0.200 |
Why?
| | Leukocytes | 1 | 2004 | 311 | 0.200 |
Why?
| | Sequence Alignment | 3 | 2021 | 344 | 0.190 |
Why?
| | Patient Transfer | 1 | 2024 | 165 | 0.190 |
Why?
| | Surveys and Questionnaires | 8 | 2024 | 5730 | 0.190 |
Why?
| | Lymphocyte Activation | 5 | 2021 | 1150 | 0.190 |
Why?
| | Africa, Southern | 2 | 2021 | 8 | 0.190 |
Why?
| | Health Services Research | 1 | 2025 | 403 | 0.190 |
Why?
| | Telomere | 4 | 2025 | 280 | 0.190 |
Why?
| | Toll-Like Receptor 3 | 1 | 2021 | 28 | 0.190 |
Why?
| | Health | 1 | 2022 | 84 | 0.190 |
Why?
| | Multilevel Analysis | 1 | 2021 | 30 | 0.190 |
Why?
| | Artificial Intelligence | 1 | 2025 | 275 | 0.190 |
Why?
| | Longevity | 1 | 2023 | 165 | 0.190 |
Why?
| | Age Factors | 5 | 2018 | 3290 | 0.180 |
Why?
| | Eczema | 1 | 2022 | 69 | 0.180 |
Why?
| | New Zealand | 3 | 2018 | 55 | 0.180 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2023 | 337 | 0.180 |
Why?
| | Genomic Structural Variation | 1 | 2021 | 12 | 0.180 |
Why?
| | Mindfulness | 1 | 2023 | 121 | 0.180 |
Why?
| | Yersinia pestis | 1 | 2021 | 45 | 0.180 |
Why?
| | Nutritionists | 1 | 2021 | 19 | 0.180 |
Why?
| | Malaysia | 1 | 2020 | 5 | 0.180 |
Why?
| | Professional Practice Location | 1 | 2021 | 30 | 0.180 |
Why?
| | HLA-DRB1 Chains | 3 | 2019 | 112 | 0.180 |
Why?
| | HLA-D Antigens | 1 | 2021 | 34 | 0.180 |
Why?
| | Protein Interaction Domains and Motifs | 2 | 2019 | 151 | 0.180 |
Why?
| | Nutritional Support | 1 | 2021 | 34 | 0.170 |
Why?
| | Plague | 1 | 2021 | 60 | 0.170 |
Why?
| | Physical Appearance, Body | 3 | 2024 | 3 | 0.170 |
Why?
| | Exercise | 5 | 2019 | 2015 | 0.170 |
Why?
| | Peripheral Arterial Disease | 2 | 2018 | 474 | 0.170 |
Why?
| | Clinical Protocols | 2 | 2019 | 268 | 0.170 |
Why?
| | Motivation | 1 | 2025 | 570 | 0.170 |
Why?
| | Thyroid Neoplasms | 1 | 2024 | 338 | 0.170 |
Why?
| | Hearing Tests | 1 | 2020 | 53 | 0.170 |
Why?
| | Child, Preschool | 7 | 2022 | 11013 | 0.160 |
Why?
| | Mentoring | 1 | 2023 | 144 | 0.160 |
Why?
| | Pregnancy | 6 | 2020 | 6715 | 0.160 |
Why?
| | Patient Acceptance of Health Care | 2 | 2024 | 798 | 0.160 |
Why?
| | Natural Cytotoxicity Triggering Receptor 2 | 1 | 2019 | 2 | 0.160 |
Why?
| | Transportation | 1 | 2019 | 51 | 0.160 |
Why?
| | Clathrin Heavy Chains | 1 | 2019 | 3 | 0.160 |
Why?
| | Protozoan Infections | 1 | 2019 | 11 | 0.160 |
Why?
| | HLA-DP Antigens | 1 | 2019 | 33 | 0.160 |
Why?
| | Diet, Diabetic | 1 | 2019 | 34 | 0.160 |
Why?
| | Health Personnel | 3 | 2021 | 696 | 0.160 |
Why?
| | B-Lymphocytes | 4 | 2017 | 844 | 0.160 |
Why?
| | Hearing | 1 | 2020 | 144 | 0.150 |
Why?
| | Diabetic Foot | 1 | 2019 | 26 | 0.150 |
Why?
| | Base Sequence | 3 | 2016 | 2180 | 0.150 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2024 | 803 | 0.150 |
Why?
| | Bicycling | 1 | 2019 | 116 | 0.150 |
Why?
| | Noninvasive Ventilation | 1 | 2019 | 51 | 0.150 |
Why?
| | Phylogeography | 1 | 2019 | 53 | 0.150 |
Why?
| | Receptors, Cell Surface | 1 | 2001 | 391 | 0.150 |
Why?
| | Indians, North American | 2 | 2015 | 624 | 0.150 |
Why?
| | Parents | 2 | 2024 | 1361 | 0.150 |
Why?
| | Sex Factors | 4 | 2019 | 2067 | 0.150 |
Why?
| | Diet | 4 | 2019 | 1261 | 0.150 |
Why?
| | Canada | 3 | 2024 | 417 | 0.150 |
Why?
| | Africa South of the Sahara | 2 | 2019 | 48 | 0.150 |
Why?
| | Leukemia, Myeloid, Acute | 2 | 2024 | 620 | 0.150 |
Why?
| | Indians, South American | 2 | 2009 | 25 | 0.150 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2018 | 54 | 0.150 |
Why?
| | Cluster Analysis | 2 | 2017 | 502 | 0.150 |
Why?
| | Receptors, Antigen, T-Cell | 3 | 2024 | 719 | 0.140 |
Why?
| | Aggression | 1 | 2020 | 210 | 0.140 |
Why?
| | ZAP-70 Protein-Tyrosine Kinase | 1 | 2017 | 10 | 0.140 |
Why?
| | Eye Diseases | 1 | 2019 | 87 | 0.140 |
Why?
| | Syk Kinase | 1 | 2017 | 21 | 0.140 |
Why?
| | Burnout, Professional | 1 | 2024 | 440 | 0.140 |
Why?
| | Middle East | 1 | 2017 | 15 | 0.140 |
Why?
| | Multifactorial Inheritance | 1 | 2019 | 174 | 0.140 |
Why?
| | Flow Cytometry | 7 | 2018 | 1185 | 0.140 |
Why?
| | Names | 1 | 2017 | 14 | 0.140 |
Why?
| | Walking | 2 | 2019 | 514 | 0.140 |
Why?
| | Structure-Activity Relationship | 1 | 2019 | 586 | 0.140 |
Why?
| | Binding Sites | 6 | 2015 | 1308 | 0.140 |
Why?
| | Genetic Testing | 4 | 2002 | 453 | 0.140 |
Why?
| | Epilepsy | 2 | 2019 | 334 | 0.140 |
Why?
| | Pan paniscus | 1 | 2017 | 4 | 0.140 |
Why?
| | Lymphocyte Subsets | 3 | 2009 | 87 | 0.140 |
Why?
| | Thrombospondin 1 | 1 | 2017 | 27 | 0.140 |
Why?
| | Contig Mapping | 1 | 2017 | 11 | 0.140 |
Why?
| | Immunodominant Epitopes | 1 | 2017 | 28 | 0.140 |
Why?
| | Pongo | 1 | 2017 | 6 | 0.140 |
Why?
| | Air Pollution | 1 | 2021 | 315 | 0.140 |
Why?
| | Osteosarcoma | 1 | 2018 | 75 | 0.140 |
Why?
| | Aorta, Abdominal | 1 | 2017 | 46 | 0.140 |
Why?
| | Prevalence | 4 | 2019 | 2709 | 0.140 |
Why?
| | Transplantation, Homologous | 4 | 2024 | 416 | 0.140 |
Why?
| | Protein Structure, Tertiary | 5 | 2015 | 869 | 0.130 |
Why?
| | Health Services Needs and Demand | 1 | 2019 | 270 | 0.130 |
Why?
| | Gene Expression Regulation | 2 | 2013 | 2615 | 0.130 |
Why?
| | Alcoholic Beverages | 1 | 2017 | 30 | 0.130 |
Why?
| | Risk Factors | 11 | 2025 | 10313 | 0.130 |
Why?
| | Antimicrobial Stewardship | 1 | 2019 | 114 | 0.130 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2017 | 101 | 0.130 |
Why?
| | Angiotensin II | 1 | 2017 | 98 | 0.130 |
Why?
| | Models, Genetic | 4 | 2015 | 607 | 0.130 |
Why?
| | Anxiety | 3 | 2023 | 1039 | 0.130 |
Why?
| | Patient Reported Outcome Measures | 1 | 2020 | 398 | 0.130 |
Why?
| | Virus Diseases | 1 | 2019 | 216 | 0.130 |
Why?
| | Open Reading Frames | 1 | 2017 | 120 | 0.130 |
Why?
| | Gene Flow | 2 | 2015 | 82 | 0.130 |
Why?
| | Reference Standards | 1 | 2017 | 182 | 0.130 |
Why?
| | Allied Health Personnel | 1 | 2016 | 46 | 0.130 |
Why?
| | Sarcoma, Ewing | 1 | 2018 | 95 | 0.130 |
Why?
| | Feeding Behavior | 2 | 2019 | 648 | 0.130 |
Why?
| | Polymerase Chain Reaction | 5 | 2017 | 1061 | 0.130 |
Why?
| | Women's Health | 1 | 2019 | 371 | 0.130 |
Why?
| | Molecular Typing | 1 | 2016 | 21 | 0.130 |
Why?
| | Placentation | 2 | 2016 | 45 | 0.130 |
Why?
| | HIV-1 | 1 | 2022 | 862 | 0.130 |
Why?
| | Self Care | 2 | 2016 | 374 | 0.130 |
Why?
| | Environmental Exposure | 1 | 2021 | 571 | 0.130 |
Why?
| | Herpesvirus 4, Human | 1 | 2017 | 167 | 0.130 |
Why?
| | Dissociative Disorders | 1 | 2015 | 22 | 0.120 |
Why?
| | Crohn Disease | 1 | 2019 | 237 | 0.120 |
Why?
| | Curriculum | 1 | 2022 | 978 | 0.120 |
Why?
| | Aged, 80 and over | 6 | 2024 | 7552 | 0.120 |
Why?
| | Protein Conformation | 1 | 2019 | 930 | 0.120 |
Why?
| | Sf9 Cells | 1 | 2015 | 9 | 0.120 |
Why?
| | Donor Selection | 1 | 2016 | 76 | 0.120 |
Why?
| | Gene Expression | 4 | 2018 | 1505 | 0.120 |
Why?
| | Spodoptera | 1 | 2015 | 40 | 0.120 |
Why?
| | Chest Pain | 1 | 2016 | 91 | 0.120 |
Why?
| | Case-Control Studies | 6 | 2024 | 3528 | 0.120 |
Why?
| | Baculoviridae | 1 | 2015 | 44 | 0.120 |
Why?
| | Human Migration | 1 | 2015 | 23 | 0.120 |
Why?
| | Potassium Channels, Inwardly Rectifying | 1 | 2015 | 38 | 0.120 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 1689 | 0.120 |
Why?
| | Bone Neoplasms | 1 | 2018 | 250 | 0.120 |
Why?
| | Insecta | 1 | 2015 | 64 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 368 | 0.120 |
Why?
| | Research Report | 1 | 2015 | 83 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 359 | 0.120 |
Why?
| | Social Class | 1 | 2017 | 277 | 0.120 |
Why?
| | Polynesia | 1 | 2014 | 4 | 0.120 |
Why?
| | Amino Acid Motifs | 5 | 2019 | 225 | 0.110 |
Why?
| | Biological Assay | 1 | 2015 | 123 | 0.110 |
Why?
| | Adolescent Behavior | 1 | 2020 | 536 | 0.110 |
Why?
| | Simian Immunodeficiency Virus | 1 | 2015 | 87 | 0.110 |
Why?
| | Receptors, KIR3DL2 | 2 | 2015 | 2 | 0.110 |
Why?
| | Time Factors | 8 | 2025 | 6802 | 0.110 |
Why?
| | Isoantibodies | 1 | 1995 | 60 | 0.110 |
Why?
| | Muscle Weakness | 1 | 2014 | 87 | 0.110 |
Why?
| | DNA | 3 | 2021 | 1460 | 0.110 |
Why?
| | Attitude of Health Personnel | 2 | 2019 | 1160 | 0.110 |
Why?
| | Risk Reduction Behavior | 1 | 2015 | 219 | 0.110 |
Why?
| | Glucose | 1 | 2019 | 1018 | 0.110 |
Why?
| | Protein Folding | 1 | 2015 | 282 | 0.110 |
Why?
| | Kidney Transplantation | 2 | 2003 | 695 | 0.110 |
Why?
| | Prospective Studies | 7 | 2024 | 7543 | 0.110 |
Why?
| | Mammals | 1 | 2015 | 286 | 0.110 |
Why?
| | Chromosomes, Human, Pair 19 | 2 | 2004 | 25 | 0.110 |
Why?
| | Tissue Donors | 4 | 2024 | 414 | 0.110 |
Why?
| | Counseling | 1 | 2016 | 392 | 0.100 |
Why?
| | Conserved Sequence | 2 | 2011 | 239 | 0.100 |
Why?
| | Cell Differentiation | 4 | 2024 | 1975 | 0.100 |
Why?
| | Species Specificity | 4 | 2017 | 593 | 0.100 |
Why?
| | Seals, Earless | 1 | 2012 | 5 | 0.100 |
Why?
| | Exome | 1 | 2014 | 231 | 0.100 |
Why?
| | Genetics, Medical | 3 | 2019 | 26 | 0.100 |
Why?
| | Hematopoietic Stem Cells | 1 | 2016 | 398 | 0.100 |
Why?
| | Prostatic Neoplasms | 1 | 2020 | 1033 | 0.100 |
Why?
| | Stress, Psychological | 2 | 2016 | 1112 | 0.100 |
Why?
| | Metagenomics | 1 | 2014 | 167 | 0.100 |
Why?
| | Anxiety Disorders | 1 | 2016 | 376 | 0.100 |
Why?
| | Hepatitis C | 1 | 2015 | 262 | 0.100 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2019 | 3697 | 0.100 |
Why?
| | Saliva | 1 | 2014 | 242 | 0.100 |
Why?
| | Graft Survival | 1 | 1995 | 539 | 0.090 |
Why?
| | CD56 Antigen | 2 | 2009 | 36 | 0.090 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2020 | 1079 | 0.090 |
Why?
| | Nervous System Diseases | 1 | 2014 | 265 | 0.090 |
Why?
| | Environment | 1 | 2013 | 362 | 0.090 |
Why?
| | Self Efficacy | 1 | 2015 | 395 | 0.090 |
Why?
| | Interviews as Topic | 2 | 2024 | 759 | 0.090 |
Why?
| | Genes, Overlapping | 1 | 2011 | 2 | 0.090 |
Why?
| | NK Cell Lectin-Like Receptor Subfamily C | 3 | 2017 | 8 | 0.090 |
Why?
| | Internet | 1 | 2015 | 652 | 0.090 |
Why?
| | Interferon-gamma | 2 | 2017 | 790 | 0.090 |
Why?
| | Hybridization, Genetic | 1 | 2011 | 77 | 0.090 |
Why?
| | Graft Rejection | 1 | 1995 | 623 | 0.090 |
Why?
| | DNA Primers | 3 | 2018 | 514 | 0.090 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2017 | 608 | 0.090 |
Why?
| | Immunoglobulin G | 1 | 1995 | 886 | 0.080 |
Why?
| | Europe | 2 | 2021 | 413 | 0.080 |
Why?
| | North America | 2 | 2021 | 312 | 0.080 |
Why?
| | Cost-Benefit Analysis | 3 | 2025 | 592 | 0.080 |
Why?
| | Family | 1 | 2014 | 667 | 0.080 |
Why?
| | Hypoglycemic Agents | 1 | 2019 | 1282 | 0.080 |
Why?
| | Mass Spectrometry | 1 | 2013 | 741 | 0.080 |
Why?
| | Gene Conversion | 1 | 2009 | 7 | 0.080 |
Why?
| | Gene Products, nef | 1 | 2009 | 12 | 0.080 |
Why?
| | Treatment Outcome | 5 | 2024 | 10768 | 0.080 |
Why?
| | Receptors, IgG | 2 | 2014 | 75 | 0.080 |
Why?
| | Transforming Growth Factor beta | 1 | 2012 | 480 | 0.080 |
Why?
| | Organ Transplantation | 1 | 2013 | 248 | 0.080 |
Why?
| | Health Services Accessibility | 1 | 2017 | 964 | 0.080 |
Why?
| | Hospitalization | 2 | 2023 | 2183 | 0.080 |
Why?
| | Algorithms | 3 | 2024 | 1695 | 0.080 |
Why?
| | Anti-Bacterial Agents | 1 | 2019 | 1790 | 0.070 |
Why?
| | Insulin | 1 | 2019 | 2389 | 0.070 |
Why?
| | Histocompatibility Antigens | 1 | 2009 | 107 | 0.070 |
Why?
| | Antigens, Bacterial | 1 | 2009 | 129 | 0.070 |
Why?
| | Africa | 3 | 2019 | 109 | 0.070 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2508 | 0.070 |
Why?
| | Nutritional Status | 2 | 2021 | 343 | 0.070 |
Why?
| | Homocysteine | 1 | 2008 | 155 | 0.070 |
Why?
| | Breast Neoplasms | 4 | 2002 | 2243 | 0.070 |
Why?
| | Databases, Factual | 1 | 2013 | 1345 | 0.070 |
Why?
| | Regression Analysis | 2 | 2021 | 1026 | 0.070 |
Why?
| | Mutagenesis, Site-Directed | 4 | 2009 | 377 | 0.070 |
Why?
| | Exotoxins | 1 | 2007 | 16 | 0.070 |
Why?
| | HIV Infections | 1 | 2022 | 2822 | 0.070 |
Why?
| | Lung Neoplasms | 1 | 2020 | 2490 | 0.070 |
Why?
| | Palliative Care | 1 | 2014 | 737 | 0.070 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2015 | 1324 | 0.070 |
Why?
| | Receptors, Fc | 1 | 2007 | 53 | 0.070 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2007 | 387 | 0.070 |
Why?
| | Genetic Counseling | 3 | 2002 | 76 | 0.060 |
Why?
| | Delivery of Health Care | 2 | 2025 | 948 | 0.060 |
Why?
| | Immunoglobulin A | 1 | 2007 | 208 | 0.060 |
Why?
| | Trinidad and Tobago | 2 | 2002 | 2 | 0.060 |
Why?
| | HLA-DR Antigens | 2 | 2006 | 228 | 0.060 |
Why?
| | Norway | 1 | 2025 | 45 | 0.060 |
Why?
| | Equivalence Trials as Topic | 1 | 2025 | 8 | 0.060 |
Why?
| | Genetic Loci | 2 | 2019 | 288 | 0.060 |
Why?
| | Ireland | 1 | 2025 | 30 | 0.060 |
Why?
| | Severity of Illness Index | 3 | 2021 | 2833 | 0.060 |
Why?
| | INDEL Mutation | 1 | 2025 | 16 | 0.060 |
Why?
| | Jurkat Cells | 2 | 2019 | 134 | 0.060 |
Why?
| | Depressive Disorder | 1 | 2008 | 383 | 0.060 |
Why?
| | Kinetochores | 1 | 2025 | 53 | 0.060 |
Why?
| | Cells, Cultured | 3 | 2017 | 4204 | 0.060 |
Why?
| | Patient Satisfaction | 3 | 2024 | 657 | 0.060 |
Why?
| | Models, Statistical | 2 | 2019 | 667 | 0.060 |
Why?
| | Cell Line, Tumor | 4 | 2015 | 3396 | 0.060 |
Why?
| | Logistic Models | 2 | 2021 | 2060 | 0.060 |
Why?
| | Whole Genome Sequencing | 1 | 2025 | 152 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2025 | 303 | 0.050 |
Why?
| | Histocompatibility | 1 | 2003 | 28 | 0.050 |
Why?
| | HeLa Cells | 2 | 2015 | 640 | 0.050 |
Why?
| | Lymphocyte Depletion | 1 | 2024 | 135 | 0.050 |
Why?
| | Leukocyte Immunoglobulin-like Receptor B1 | 1 | 2003 | 2 | 0.050 |
Why?
| | Polymorphism, Single-Stranded Conformational | 1 | 2003 | 26 | 0.050 |
Why?
| | Microsatellite Repeats | 1 | 2004 | 168 | 0.050 |
Why?
| | Granzymes | 1 | 2023 | 49 | 0.050 |
Why?
| | Cell Communication | 1 | 2005 | 313 | 0.050 |
Why?
| | Staphylococcus aureus | 1 | 2007 | 451 | 0.050 |
Why?
| | Human Immunodeficiency Virus Proteins | 1 | 2022 | 6 | 0.050 |
Why?
| | Lymphocytes | 1 | 2005 | 393 | 0.050 |
Why?
| | Gene Library | 2 | 2014 | 117 | 0.050 |
Why?
| | Viral Regulatory and Accessory Proteins | 1 | 2022 | 28 | 0.050 |
Why?
| | Neoplasms | 1 | 2017 | 2655 | 0.050 |
Why?
| | Africa, Western | 1 | 2002 | 17 | 0.050 |
Why?
| | Chromosomes, Human | 1 | 2002 | 44 | 0.050 |
Why?
| | Pakistan | 1 | 2002 | 76 | 0.050 |
Why?
| | Bangladesh | 1 | 2002 | 56 | 0.050 |
Why?
| | Risk Assessment | 4 | 2019 | 3432 | 0.050 |
Why?
| | Pandemics | 2 | 2021 | 1615 | 0.050 |
Why?
| | HLA-DQ Antigens | 1 | 2002 | 181 | 0.050 |
Why?
| | Cloning, Molecular | 2 | 2014 | 536 | 0.050 |
Why?
| | India | 1 | 2002 | 193 | 0.050 |
Why?
| | Software Design | 1 | 2021 | 24 | 0.050 |
Why?
| | Single-Cell Analysis | 1 | 2024 | 309 | 0.050 |
Why?
| | Hydroxychloroquine | 1 | 2021 | 59 | 0.050 |
Why?
| | Databases, Nucleic Acid | 1 | 2021 | 34 | 0.050 |
Why?
| | Quantitative Trait, Heritable | 1 | 2002 | 126 | 0.040 |
Why?
| | Thailand | 1 | 2001 | 17 | 0.040 |
Why?
| | Bacterial Proteins | 1 | 2007 | 889 | 0.040 |
Why?
| | Nutrition Assessment | 1 | 2021 | 90 | 0.040 |
Why?
| | Odds Ratio | 2 | 2017 | 1063 | 0.040 |
Why?
| | Mice | 4 | 2024 | 17775 | 0.040 |
Why?
| | Geography | 1 | 2021 | 197 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2025 | 658 | 0.040 |
Why?
| | Confidence Intervals | 1 | 2021 | 328 | 0.040 |
Why?
| | Prosthesis Design | 1 | 2022 | 309 | 0.040 |
Why?
| | Cholesterol, HDL | 1 | 2021 | 205 | 0.040 |
Why?
| | Risk | 2 | 2019 | 905 | 0.040 |
Why?
| | Leadership | 1 | 2024 | 376 | 0.040 |
Why?
| | Twins | 1 | 2001 | 253 | 0.040 |
Why?
| | Breathing Exercises | 1 | 2019 | 21 | 0.040 |
Why?
| | Respiratory Muscles | 1 | 2019 | 33 | 0.040 |
Why?
| | Genetic Markers | 1 | 2001 | 345 | 0.040 |
Why?
| | Newfoundland and Labrador | 1 | 2019 | 1 | 0.040 |
Why?
| | Adolescent Nutritional Physiological Phenomena | 1 | 2019 | 27 | 0.040 |
Why?
| | Patient Acuity | 1 | 2019 | 45 | 0.040 |
Why?
| | Electric Impedance | 1 | 2019 | 109 | 0.040 |
Why?
| | Deglutition | 1 | 2019 | 72 | 0.040 |
Why?
| | Hospitals, Rural | 1 | 2019 | 39 | 0.040 |
Why?
| | Hospital Units | 1 | 2019 | 26 | 0.040 |
Why?
| | Ketones | 1 | 2019 | 51 | 0.040 |
Why?
| | Interrupted Time Series Analysis | 1 | 2019 | 65 | 0.040 |
Why?
| | Autophagy | 1 | 2021 | 282 | 0.040 |
Why?
| | Cytotoxicity Tests, Immunologic | 2 | 2009 | 41 | 0.040 |
Why?
| | Hospitals, Community | 1 | 2019 | 50 | 0.040 |
Why?
| | Celiac Disease | 1 | 2002 | 291 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2021 | 734 | 0.040 |
Why?
| | Nucleic Acid Denaturation | 1 | 2018 | 32 | 0.040 |
Why?
| | Group Processes | 1 | 2019 | 61 | 0.040 |
Why?
| | Monitoring, Ambulatory | 1 | 2019 | 86 | 0.040 |
Why?
| | Research Design | 1 | 2025 | 1108 | 0.040 |
Why?
| | Hepatitis B | 1 | 2019 | 71 | 0.040 |
Why?
| | Western Australia | 1 | 2018 | 8 | 0.040 |
Why?
| | Mutation | 3 | 2020 | 3948 | 0.040 |
Why?
| | Limit of Detection | 1 | 2018 | 86 | 0.040 |
Why?
| | Cough | 1 | 2019 | 121 | 0.040 |
Why?
| | Triglycerides | 1 | 2021 | 524 | 0.040 |
Why?
| | Posture | 1 | 2019 | 181 | 0.040 |
Why?
| | Disease Models, Animal | 3 | 2017 | 4281 | 0.040 |
Why?
| | Disease Progression | 2 | 2017 | 2744 | 0.040 |
Why?
| | Chromosome Mapping | 2 | 2014 | 523 | 0.040 |
Why?
| | Narration | 1 | 2019 | 58 | 0.040 |
Why?
| | Particulate Matter | 1 | 2021 | 313 | 0.040 |
Why?
| | Environmental Monitoring | 1 | 2021 | 369 | 0.040 |
Why?
| | Body Height | 1 | 2019 | 201 | 0.040 |
Why?
| | Protein Kinase Inhibitors | 1 | 2024 | 919 | 0.040 |
Why?
| | Parenting | 1 | 2022 | 311 | 0.040 |
Why?
| | Ankle Brachial Index | 1 | 2018 | 37 | 0.040 |
Why?
| | Tertiary Care Centers | 1 | 2019 | 160 | 0.040 |
Why?
| | Biomarkers | 2 | 2021 | 4148 | 0.040 |
Why?
| | T-Lymphocyte Subsets | 1 | 2000 | 425 | 0.040 |
Why?
| | Recurrence | 1 | 2021 | 1058 | 0.040 |
Why?
| | Deglutition Disorders | 1 | 2019 | 143 | 0.040 |
Why?
| | Collagen Type III | 1 | 2017 | 16 | 0.030 |
Why?
| | Low Density Lipoprotein Receptor-Related Protein-1 | 1 | 2017 | 18 | 0.030 |
Why?
| | Arthritis, Rheumatoid | 1 | 2006 | 1159 | 0.030 |
Why?
| | Demography | 2 | 2013 | 291 | 0.030 |
Why?
| | Butyrophilins | 1 | 2017 | 6 | 0.030 |
Why?
| | NK Cell Lectin-Like Receptor Subfamily K | 1 | 2017 | 6 | 0.030 |
Why?
| | Workflow | 1 | 2018 | 165 | 0.030 |
Why?
| | Age Distribution | 1 | 2018 | 391 | 0.030 |
Why?
| | Health Care Surveys | 1 | 2019 | 565 | 0.030 |
Why?
| | Sex Distribution | 1 | 2018 | 378 | 0.030 |
Why?
| | Receptors, LDL | 1 | 2017 | 49 | 0.030 |
Why?
| | Chromosomes, Artificial, Bacterial | 1 | 2017 | 19 | 0.030 |
Why?
| | Health Equity | 1 | 2019 | 98 | 0.030 |
Why?
| | Elastin | 1 | 2017 | 78 | 0.030 |
Why?
| | Lymphocyte Count | 3 | 2002 | 150 | 0.030 |
Why?
| | Gorilla gorilla | 1 | 2017 | 22 | 0.030 |
Why?
| | Graft vs Host Disease | 1 | 2019 | 248 | 0.030 |
Why?
| | Triage | 1 | 2019 | 217 | 0.030 |
Why?
| | Apolipoproteins E | 1 | 2017 | 84 | 0.030 |
Why?
| | ErbB Receptors | 1 | 2020 | 616 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2018 | 403 | 0.030 |
Why?
| | Computer Simulation | 1 | 2021 | 984 | 0.030 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2017 | 132 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2017 | 5126 | 0.030 |
Why?
| | Cross Infection | 1 | 2019 | 238 | 0.030 |
Why?
| | Proteolysis | 1 | 2017 | 179 | 0.030 |
Why?
| | Quality-Adjusted Life Years | 1 | 2016 | 111 | 0.030 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2024 | 843 | 0.030 |
Why?
| | Germ-Line Mutation | 1 | 2017 | 171 | 0.030 |
Why?
| | Antibodies, Monoclonal | 2 | 2018 | 1417 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2017 | 401 | 0.030 |
Why?
| | Liver | 1 | 2005 | 1937 | 0.030 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 232 | 0.030 |
Why?
| | Respiratory Insufficiency | 1 | 2019 | 316 | 0.030 |
Why?
| | CD57 Antigens | 1 | 2015 | 18 | 0.030 |
Why?
| | Intention to Treat Analysis | 1 | 2015 | 75 | 0.030 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2017 | 99 | 0.030 |
Why?
| | Siberia | 1 | 2015 | 9 | 0.030 |
Why?
| | Autoantibodies | 1 | 2023 | 1498 | 0.030 |
Why?
| | Patient Participation | 1 | 2019 | 423 | 0.030 |
Why?
| | Americas | 1 | 2015 | 28 | 0.030 |
Why?
| | K562 Cells | 1 | 2015 | 89 | 0.030 |
Why?
| | Nursing Staff | 1 | 2016 | 46 | 0.030 |
Why?
| | Adaptive Immunity | 1 | 2016 | 164 | 0.030 |
Why?
| | Leukemia, Myeloid | 1 | 2015 | 45 | 0.030 |
Why?
| | History, Ancient | 1 | 2015 | 54 | 0.030 |
Why?
| | Cytotoxicity, Immunologic | 2 | 2008 | 225 | 0.030 |
Why?
| | Vascular Remodeling | 1 | 2017 | 190 | 0.030 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2001 | 1092 | 0.030 |
Why?
| | Down-Regulation | 1 | 2017 | 658 | 0.030 |
Why?
| | Attitude | 1 | 2017 | 260 | 0.030 |
Why?
| | Databases, Genetic | 1 | 2016 | 237 | 0.030 |
Why?
| | Evidence-Based Medicine | 1 | 2019 | 744 | 0.030 |
Why?
| | Patient Care Team | 1 | 2000 | 624 | 0.030 |
Why?
| | Program Evaluation | 1 | 2019 | 889 | 0.030 |
Why?
| | DNA Damage | 1 | 2017 | 420 | 0.030 |
Why?
| | Chromosomes, Mammalian | 1 | 2014 | 25 | 0.030 |
Why?
| | Fruit | 1 | 2015 | 138 | 0.030 |
Why?
| | Terminology as Topic | 1 | 2016 | 212 | 0.030 |
Why?
| | South Africa | 1 | 2015 | 219 | 0.030 |
Why?
| | Social Support | 1 | 2019 | 614 | 0.030 |
Why?
| | Tumor Suppressor Proteins | 1 | 2017 | 328 | 0.030 |
Why?
| | Genetic Fitness | 1 | 2015 | 57 | 0.030 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2019 | 345 | 0.030 |
Why?
| | Vegetables | 1 | 2015 | 150 | 0.030 |
Why?
| | Inpatients | 1 | 2019 | 497 | 0.030 |
Why?
| | Hypoglycemia | 1 | 2019 | 442 | 0.030 |
Why?
| | Smoking Prevention | 1 | 2015 | 188 | 0.030 |
Why?
| | Patient Education as Topic | 1 | 2019 | 762 | 0.030 |
Why?
| | Bone Marrow Transplantation | 1 | 2015 | 286 | 0.030 |
Why?
| | United States | 2 | 2023 | 14595 | 0.030 |
Why?
| | Caribbean Region | 1 | 2013 | 26 | 0.030 |
Why?
| | Bone Marrow | 1 | 2015 | 286 | 0.030 |
Why?
| | Models, Psychological | 1 | 2015 | 311 | 0.030 |
Why?
| | Mouth | 1 | 2014 | 86 | 0.030 |
Why?
| | Transplant Recipients | 1 | 2015 | 176 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2024 | 5766 | 0.030 |
Why?
| | Hepacivirus | 1 | 2015 | 257 | 0.030 |
Why?
| | Reproduction | 1 | 2015 | 203 | 0.030 |
Why?
| | Genetic Association Studies | 1 | 2015 | 377 | 0.030 |
Why?
| | Guidelines as Topic | 1 | 2015 | 277 | 0.030 |
Why?
| | Lung | 2 | 2019 | 4046 | 0.030 |
Why?
| | Asia | 2 | 2003 | 70 | 0.030 |
Why?
| | Ultrasonography | 1 | 2017 | 749 | 0.030 |
Why?
| | Cultural Competency | 1 | 2014 | 87 | 0.030 |
Why?
| | Ursidae | 1 | 2012 | 7 | 0.020 |
Why?
| | Smad Proteins | 1 | 2012 | 42 | 0.020 |
Why?
| | Acute Disease | 1 | 2015 | 1000 | 0.020 |
Why?
| | Cell Membrane | 1 | 2016 | 751 | 0.020 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2012 | 59 | 0.020 |
Why?
| | Genome | 1 | 2014 | 292 | 0.020 |
Why?
| | Physical Therapy Modalities | 1 | 1975 | 309 | 0.020 |
Why?
| | DNA, Mitochondrial | 1 | 2013 | 201 | 0.020 |
Why?
| | Host-Pathogen Interactions | 1 | 2015 | 367 | 0.020 |
Why?
| | Cattle | 1 | 2014 | 982 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2016 | 943 | 0.020 |
Why?
| | Feces | 1 | 2015 | 477 | 0.020 |
Why?
| | Pregnancy Proteins | 1 | 2011 | 36 | 0.020 |
Why?
| | Quantitative Trait Loci | 1 | 2014 | 381 | 0.020 |
Why?
| | Pulmonary Veins | 1 | 1992 | 99 | 0.020 |
Why?
| | Smoking Cessation | 1 | 2015 | 446 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2019 | 3282 | 0.020 |
Why?
| | Family Practice | 1 | 1975 | 467 | 0.020 |
Why?
| | Models, Biological | 2 | 2016 | 1774 | 0.020 |
Why?
| | Dogs | 1 | 2012 | 411 | 0.020 |
Why?
| | Adaptation, Biological | 1 | 2011 | 56 | 0.020 |
Why?
| | Immunologic Memory | 1 | 2013 | 368 | 0.020 |
Why?
| | Diabetes Mellitus | 1 | 2019 | 1033 | 0.020 |
Why?
| | HLA-A2 Antigen | 1 | 2011 | 48 | 0.020 |
Why?
| | Aortic Aneurysm, Thoracic | 1 | 2012 | 131 | 0.020 |
Why?
| | Twins, Dizygotic | 2 | 2001 | 183 | 0.020 |
Why?
| | Uterus | 1 | 2011 | 215 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2012 | 366 | 0.020 |
Why?
| | MAP Kinase Signaling System | 1 | 2012 | 322 | 0.020 |
Why?
| | Prognosis | 1 | 2019 | 4011 | 0.020 |
Why?
| | Twins, Monozygotic | 2 | 2001 | 213 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2017 | 2998 | 0.020 |
Why?
| | Culture | 1 | 2011 | 129 | 0.020 |
Why?
| | HLA-A11 Antigen | 1 | 2009 | 1 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 1995 | 1945 | 0.020 |
Why?
| | Antibody Affinity | 1 | 2009 | 60 | 0.020 |
Why?
| | Receptors, KIR2DL5 | 1 | 2009 | 1 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2017 | 2471 | 0.020 |
Why?
| | Leucine | 1 | 2009 | 111 | 0.020 |
Why?
| | Substrate Specificity | 1 | 2009 | 385 | 0.020 |
Why?
| | Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2008 | 36 | 0.020 |
Why?
| | Pyridoxine | 1 | 2008 | 36 | 0.020 |
Why?
| | Protein Structure, Secondary | 1 | 2009 | 373 | 0.020 |
Why?
| | Aging | 1 | 2019 | 1863 | 0.020 |
Why?
| | Personality Inventory | 1 | 2008 | 142 | 0.020 |
Why?
| | Clone Cells | 1 | 2008 | 266 | 0.020 |
Why?
| | Crystallography, X-Ray | 1 | 2009 | 474 | 0.020 |
Why?
| | Tryptophan | 1 | 2009 | 183 | 0.020 |
Why?
| | Vitamin B 12 | 1 | 2008 | 126 | 0.020 |
Why?
| | Folic Acid | 1 | 2008 | 186 | 0.020 |
Why?
| | Hemodynamics | 1 | 2012 | 1114 | 0.020 |
Why?
| | Peptide Fragments | 1 | 2011 | 707 | 0.020 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2011 | 853 | 0.020 |
Why?
| | Lysine | 1 | 2009 | 297 | 0.020 |
Why?
| | Venezuela | 1 | 2006 | 8 | 0.020 |
Why?
| | Myeloid Cells | 1 | 2007 | 146 | 0.020 |
Why?
| | Microbiota | 1 | 2014 | 763 | 0.020 |
Why?
| | Rabbits | 1 | 2007 | 792 | 0.020 |
Why?
| | CD4-CD8 Ratio | 1 | 2005 | 22 | 0.010 |
Why?
| | CD8 Antigens | 1 | 2005 | 75 | 0.010 |
Why?
| | Placenta | 1 | 2011 | 749 | 0.010 |
Why?
| | Leukocyte Common Antigens | 1 | 2005 | 87 | 0.010 |
Why?
| | Microspheres | 1 | 2005 | 137 | 0.010 |
Why?
| | Cell Separation | 1 | 2005 | 319 | 0.010 |
Why?
| | Immunophenotyping | 1 | 2005 | 318 | 0.010 |
Why?
| | Oligonucleotide Probes | 1 | 2003 | 51 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2008 | 1255 | 0.010 |
Why?
| | HLA-DQ alpha-Chains | 1 | 2002 | 16 | 0.010 |
Why?
| | Membrane Proteins | 1 | 2009 | 1167 | 0.010 |
Why?
| | HLA-DQ beta-Chains | 1 | 2002 | 63 | 0.010 |
Why?
| | Postoperative Period | 1 | 2003 | 344 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2008 | 1460 | 0.010 |
Why?
| | Cyclosporine | 1 | 2003 | 268 | 0.010 |
Why?
| | Genes, bcl-2 | 1 | 2002 | 21 | 0.010 |
Why?
| | Utah | 1 | 2002 | 69 | 0.010 |
Why?
| | Living Donors | 1 | 2003 | 295 | 0.010 |
Why?
| | Cytokines | 1 | 2009 | 2078 | 0.010 |
Why?
| | Chi-Square Distribution | 1 | 2001 | 533 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2018 | 15514 | 0.010 |
Why?
| | Genes, BRCA1 | 1 | 2000 | 38 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 2000 | 177 | 0.010 |
Why?
| | BRCA2 Protein | 1 | 2000 | 63 | 0.010 |
Why?
| | Immunosuppressive Agents | 1 | 2003 | 886 | 0.010 |
Why?
| | Ambulatory Care Facilities | 1 | 2000 | 233 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 2001 | 1524 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2000 | 1324 | 0.010 |
Why?
| | Neoplasm Proteins | 1 | 2000 | 432 | 0.010 |
Why?
| | Autoimmune Diseases | 1 | 2000 | 459 | 0.010 |
Why?
| | Hospital Departments | 1 | 1975 | 10 | 0.010 |
Why?
| | Referral and Consultation | 1 | 2000 | 779 | 0.010 |
Why?
| | Receptors, Leukotriene B4 | 1 | 1992 | 7 | 0.010 |
Why?
| | SRS-A | 1 | 1992 | 31 | 0.010 |
Why?
| | Receptors, Leukotriene | 1 | 1992 | 14 | 0.010 |
Why?
| | Dicarboxylic Acids | 1 | 1992 | 8 | 0.010 |
Why?
| | Leukotriene E4 | 1 | 1992 | 27 | 0.010 |
Why?
| | Propionates | 1 | 1992 | 39 | 0.010 |
Why?
| | Transcription Factors | 1 | 2000 | 1715 | 0.010 |
Why?
| | Cysteine | 1 | 1992 | 206 | 0.010 |
Why?
| | Muscle Contraction | 1 | 1992 | 428 | 0.000 |
Why?
|
|
Norman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|